G
Gerhard Ehninger
Researcher at Dresden University of Technology
Publications - 627
Citations - 30962
Gerhard Ehninger is an academic researcher from Dresden University of Technology. The author has contributed to research in topics: Transplantation & Myeloid leukemia. The author has an hindex of 73, co-authored 610 publications receiving 26790 citations. Previous affiliations of Gerhard Ehninger include German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
Christian Thiede,Christine Steudel,Brigitte Mohr,Markus Schaich,Ulrike Schäkel,Uwe Platzbecker,Martin Wermke,Martin Bornhäuser,Markus Ritter,Andreas Neubauer,Gerhard Ehninger,Thomas Illmer +11 more
TL;DR: In this paper, the authors analyzed the prevalence and the potential prognostic impact of FLT3 mutations in 979 acute myelogenous leukemia (AML) patients and found that a high mutant/wt ratio in ITD-positive patients appears to have a major impact on the prognostic relevance.
Journal ArticleDOI
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Richard Stone,Sumithra J. Mandrekar,Ben L. Sanford,Kristina Laumann,Susan Geyer,Clara D. Bloomfield,Christian Thiede,Thomas W. Prior,Konstanze Döhner,Guido Marcucci,Francesco Lo-Coco,Rebecca B. Klisovic,Andrew H. Wei,Jorge Sierra,Miguel A. Sanz,Joseph Brandwein,Theo de Witte,Dietger Niederwieser,Frederick R. Appelbaum,Bruno C. Medeiros,Martin S. Tallman,Jürgen Krauter,Richard F. Schlenk,Arnold Ganser,Hubert Serve,Gerhard Ehninger,Sergio Amadori,Richard A. Larson,Hartmut Döhner +28 more
TL;DR: The addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy significantly prolonged overall and event‐free survival among patients with AML and a FLT3 mutation.
Journal ArticleDOI
Mesenchymal stem cells can be differentiated into endothelial cells in vitro.
Joachim Oswald,Sabine Boxberger,Birgitte Jørgensen,Silvia Feldmann,Gerhard Ehninger,Martin Bornhäuser,Carsten Werner +6 more
TL;DR: The differentiation of expanded adult human MSCs into cells with phenotypic and functional features of endothelial cells are shown to provide new options for engineering of artificial tissues based on autologous M SCs and vascularized engineered tissues.
Journal ArticleDOI
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
Francesco Lo-Coco,Giuseppe Avvisati,Marco Vignetti,Christian Thiede,Simona Iacobelli,Felicetto Ferrara,Paola Fazi,Laura Cicconi,E. Di Bona,Giorgina Specchia,Simona Sica,Mariadomenica Divona,Alessandro Levis,Walter Fiedler,Elisa Cerqui,Massimo Breccia,Giuseppe Fioritoni,Mario Cazzola,L. Melillo,Enrica Morra,Bernd Hertenstein,Mohammed Wattad,Michael Lübbert,Mathias Hänel,Norbert Schmitz,Alessandro Rambaldi,G. La Nasa,Mario Luppi,Fabio Ciceri,Olimpia Finizio,Adriano Venditti,Francesco Fabbiano,Konstanze Döhner,M. Sauer,Arnold Ganser,Sergio Amadori,Franco Mandelli,Hartmut Döhner,Gerhard Ehninger +38 more
TL;DR: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL.
Journal ArticleDOI
Acute myeloid leukaemia.
Asim Khwaja,Magnus Björkholm,Rosemary E. Gale,Ross L. Levine,Craig T. Jordan,Gerhard Ehninger,Clara D. Bloomfield,Eli Estey,Alan Kenneth Burnett,Jan J. Cornelissen,David A. Scheinberg,Didier Bouscary,David C. Linch +12 more
TL;DR: A plethora of new agents — including those targeted at specific biochemical pathways and immunotherapeutic approaches — are now in trial based on improved understanding of disease pathophysiology, providing good grounds for optimism, although mortality remains high especially in older patients.